CSL

Now Accepting Reservations: Newest Four Seasons Resort in Mexico Will Welcome Guests to Cabo's Famous Golden Corridor Beginning May 1, 2024

Retrieved on: 
星期二, 二月 27, 2024
Accor, Love, Wine, Sea, Restaurant, Architecture, Multimedia, Los Cabos International Airport, Baja California peninsula, Friends, CSL, SJD, Letter, Food, Life, Golden Corridor, Pacific coast, Nikkei, CABO, Heart, Music, Hotel

CABO SAN LUCAS, Mexico, Feb. 27, 2024 /PRNewswire/ -- Four Seasons Resort and Residences Cabo San Lucas at Cabo Del Sol is open for reservations and will begin welcoming guests as of May 1, 2024. Ideally located on the stunning southern coast of the Baja in the heart of the Los Cabos Golden Corridor, the luxury resort community of Cabo Del Sol is home to a vibrant, Riviera-style village that includes the new Four Seasons Resort and Residences.

Key Points: 
  • "With this project, guests will enjoy all that this thriving scene has to offer, paired with Four Seasons hospitality and heart that they have come to love in Mexico and beyond."
  • With clean lines and open, airy spaces, the architecture and design seamlessly blend traditional Mexican influences with contemporary luxury.
  • Be among the first to experience the all-new Four Seasons Resort Cabo San Luas at Cabo Del Sol: Four Seasons is currently confirming arrivals starting May 1, 2024.
  • The company is also located in the capital on historic Paseo de la Reforma avenue at Four Seasons Hotel Mexico City.

Genezen Enters Licensing Agreement with CSL for the Cytegrity™ Stable Lentivirus Production System

Retrieved on: 
星期三, 二月 21, 2024
Biotechnology, CSL, GMP, CDMO, Safety, LVV, Patient, CSO, Immortalised cell line, Vaccine

FISHERS, Ind. and BOSTON, Feb. 21, 2024 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL.

Key Points: 
  • Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to cutting edge technology for stable and scalable high-titer clinical lentivirus production.
  • and BOSTON, Feb. 21, 2024 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL.
  • Cytegrity™ is an advanced inducible stable producer technology designed for the production of lentiviral vectors (LVVs).
  • We have significant, hands-on experience scaling up and producing LVV using this stable production system at our GMP vector facility in Fishers, Indiana.

ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112

Retrieved on: 
星期四, 二月 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Safety, CSL, MACE, AMI, Patient, Risk

ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI), did not meet its primary efficacy endpoint of MACE reduction at 90 days.

Key Points: 
  • ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI), did not meet its primary efficacy endpoint of MACE reduction at 90 days.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
星期二, 二月 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
星期二, 二月 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])

Retrieved on: 
星期日, 二月 11, 2024
Caregiver, AEGIS, AMI, Apolipoprotein, CSL, MACE, Risk, Safety, ASX, History, American College, Patient, Harvard Medical School

The study did not meet its primary efficacy endpoint of MACE reduction at 90 days.

Key Points: 
  • The study did not meet its primary efficacy endpoint of MACE reduction at 90 days.
  • As a result, there are no plans for a near-term regulatory filing.
  • There were no major safety or tolerability concerns with CSL112.
  • "We will continue to analyze the findings and share the full results in the coming months."

INTRODUCING CSL SATELLITE - CRITICAL IOT CONNECTIVITY

Retrieved on: 
星期四, 二月 8, 2024
Starlink, Multimedia, LEO, Light, CSL

LONDON, Feb. 8, 2024 /PRNewswire/ -- CSL, Critical IoT Connectivity experts, announce the launch of CSL Satellite.

Key Points: 
  • LONDON, Feb. 8, 2024 /PRNewswire/ -- CSL, Critical IoT Connectivity experts, announce the launch of CSL Satellite.
  • CSL Satellite provides Critical Connectivity to remote or challenging environments, where mobile or fixed broadband options are unavailable or unreliable.
  • This resilient, encrypted Critical Connectivity is provided via Starlink's constellation of low Earth orbit (LEO) satellites, along with CSL's managed service which includes 24/7 support.
  • CSL's Head of Product, Andy Bromley, commented: "CSL has been an industry leader in providing Critical Connectivity to worldwide, leading brands for over 25 years.

INTRODUCING CSL SATELLITE - CRITICAL IOT CONNECTIVITY

Retrieved on: 
星期四, 二月 8, 2024
Starlink, LEO, Light, CSL, Communications satellite

LONDON, Feb. 8, 2024 /PRNewswire/ -- CSL, Critical IoT Connectivity experts, announce the launch of CSL Satellite.

Key Points: 
  • LONDON, Feb. 8, 2024 /PRNewswire/ -- CSL, Critical IoT Connectivity experts, announce the launch of CSL Satellite.
  • CSL Satellite provides Critical Connectivity to remote or challenging environments, where mobile or fixed broadband options are unavailable or unreliable.
  • This resilient, encrypted Critical Connectivity is provided via Starlink's constellation of low Earth orbit (LEO) satellites, along with CSL's managed service which includes 24/7 support.
  • CSL's Head of Product, Andy Bromley, commented: "CSL has been an industry leader in providing Critical Connectivity to worldwide, leading brands for over 25 years.

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

Retrieved on: 
星期一, 二月 5, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, Pfizer–BioNTech COVID-19 vaccine, SARS-CoV-2, Senior, RNA, Arcturus, ARCT, GMT, Messenger, CSL, Therapy, ASX, Arcturus Therapeutics, Vaccine

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.

Key Points: 
  • Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.
  • ARCT-154 was administered at one-sixth the dose of Comirnaty® (5 μg vs 30 μg, respectively).
  • “These results further support sa-mRNA’s differentiating attribute to provide prolonged protection against COVID-19 at lower doses,” said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL.
  • GMTs against Wuhan-Hu-1 remained numerically higher 180 days after ARCT-154 than those observed 28 days after the Comirnaty® booster.